<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Taba">
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td align="left">Medicines authorised between 2006 and 2017 without additional risk minimisation measures (aRMMs) have a low probability that aRMMs will be introduced within 5 and 10Â years after authorisation, and medicines authorised with aRMMs during that period have a low probability that aRMMs will be discontinued.</td>
   </tr>
   <tr>
    <td align="left">Post-authorisation introduction of aRMMs is most often triggered by new safety information arising from spontaneous reports or clinical trials.</td>
   </tr>
   <tr>
    <td align="left">The role of effectiveness evaluation of aRMMs in the life cycle management of medicines is currently unclear.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
